315 related articles for article (PubMed ID: 23510862)
1. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
Garcia JA; Elson P; Tyler A; Triozzi P; Dreicer R
Urol Oncol; 2014 Jan; 32(1):33.e11-7. PubMed ID: 23510862
[TBL] [Abstract][Full Text] [Related]
2. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Nabhan C; Patel A; Villines D; Tolzien K; Kelby SK; Lestingi TM
Clin Genitourin Cancer; 2014 Feb; 12(1):27-32. PubMed ID: 24238760
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naïve adenocarcinoma of the prostate.
Amato RJ; Hernandez-McClain J; Henary H
Urol Oncol; 2009; 27(1):8-13. PubMed ID: 18367123
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma.
Garcia JA; Klein EA; Magi-Galluzzi C; Elson P; Triozzi P; Dreicer R
Clin Cancer Res; 2008 May; 14(10):3052-9. PubMed ID: 18483371
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
[TBL] [Abstract][Full Text] [Related]
7. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
[TBL] [Abstract][Full Text] [Related]
8. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
Mathew P; Tannir N; Tu SM; Carter CM; Bekele NB; Pagliaro L
Cancer Chemother Pharmacol; 2010 Mar; 65(4):811-5. PubMed ID: 20052472
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide in treating patients with castration-resistant prostate cancer.
Xing DL; Song DK; Zhang LR
Asian Pac J Cancer Prev; 2015; 16(9):3969-72. PubMed ID: 25987070
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments.
Amato RJ; Saxena S; Stepankiw M
Cancer Invest; 2013 Mar; 31(3):177-82. PubMed ID: 23402284
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Amato RJ; Sarao H
Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
[TBL] [Abstract][Full Text] [Related]
13. Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study.
Barata PC; Cooney M; Mendiratta P; Tyler A; Dreicer R; Garcia JA
Invest New Drugs; 2018 Dec; 36(6):1085-1092. PubMed ID: 30191523
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer.
Dreicer R; Klein EA; Elson P; Peereboom D; Byzova T; Plow EF
Urol Oncol; 2005; 23(2):82-6. PubMed ID: 15869991
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
16. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
17. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
18. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.
Rini BI; Fong L; Weinberg V; Kavanaugh B; Small EJ
J Urol; 2006 Jun; 175(6):2087-91. PubMed ID: 16697809
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
